Shares of Health Care sector company Intra-Cellular Therapies moved -0.8% today, and are now trading at a price of $56.53. The mid-cap stock's daily volume was 37,299 compared to its average volume of 652,998. The S&P 500 index returned a -0.0% performance.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company is based in New York and has 561 full time employees. Its market capitalization is $5,432,538,624.
12 analysts are following Intra-Cellular Therapies and have set target prices ranging from $59.0 to $100.0 per share. On average, they have given the company a rating of buy. At today's prices, ITCI is trading -27.52% away from its average analyst target price of $78.0 per share.
Over the last year, ITCI's share price has increased by 8.0%, which represents a difference of -6.0% when compared to the S&P 500. The stock's 52 week high is $67.05 per share whereas its 52 week low is $42.01.
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2023-03-01 | -270,186 | -778 | -269,408 | -3.93 |
| 2022-03-01 | -259,544 | -325 | -259,219 | -12.8 |
| 2021-02-25 | -230,073 | -267 | -229,806 | -80.55 |
| 2020-03-02 | -127,983 | -700 | -127,283 | -8.07 |
| 2019-02-27 | -118,169 | -391 | -117,778 | -47.65 |
| 2018-03-01 | -80,492 | -723 | -79,768 |
